![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, October 14, 2018 2:54:19 PM
Kevetrin has proven itself in every study it has been in and is already quite far along in developing it into a oral delivery system per IPIX statements in the spring of 2017. It has been on hold due to financial assets being diverted to B and P, but it certainly is as viable as ever. Many seem to forget that the p53 gene, which Kevetrin has shown to activate, is the most researched and published matter in the history of medicine. There is no possible way the medical field will not jump on Kevetrin, when in pill form, with both feet in a big way.
The only hangup with Prurisol is getting the release of the P2b data and that seems to be going to be worked out in the near future with the recent financing. The only problem with the science of Prurisol is in the minds of those posting here regularly that have no foundation whatsoever for their disparaging remarks. Remember, the psoriasis indication is a biggie, but certainly not the biggest of the markets for Prurisol. Like Kevetrin, it has never failed in a trial of any sort in it's history. So to think it doesn't have a great future of becoming a powerhouse drug IMO is way off base and will be proved wrong in the near future.
I understand the hesitation in deeming them powerhouses with no reservations, but all those reservations should be addressed by the end of the year IMO.
Looking forward to another week where expectations for further PRs are running high and they will take everyone by surprise as have the PRs of the past couple of weeks. Exciting times for us longs!!!
Is you moniker based on the John Cleese British comedy show years ago? Too bad it was so short lived as it was wonderful IMO.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM